Goldman Sachs initiates Soleno Therapeutics stock with Buy rating on Vykat potential
PositiveFinancial Markets

Goldman Sachs has given a Buy rating to Soleno Therapeutics, highlighting the potential of its drug Vykat. This endorsement is significant as it suggests confidence in the company's future growth and the effectiveness of its product, which could lead to increased investor interest and potentially higher stock prices.
— Curated by the World Pulse Now AI Editorial System